All Type of News
Why Korea Pharmaceutical Manufacturers Association include Bio-Pharm in its name?
The Korea Pharmaceutical Manufacturers Association, which was originated from the Joseon Pharmaceutical Association after participated by 65 pharmaceutical companies on October 1945, is planning to change its name to ...
Listed pharmaceutical companies significantly raise exports in first half
While pharmaceutical companies are following the ‘drive’ policy in exportation, their exports and foreign sales were largely increased in the first half of the year. In particular, the growth rate of KOSDAQ listed pha...
Government plans to cut insurance registration period to less than 240 days
The new antibodies’ insurance registration period is expected to be drastically decreased.
The Ministry of Health and Welfare(Minister Jin-yup Jung, MOHW) and the Health Insurance Review & Assessment Service(Chief D...
Listed pharmaceuticals earn KRW 75 from selling products of KRW 1,000
Listed pharmaceutical companies were analyzed to generate KRW 75 by selling manufactured goods(including products) of KRW 1,000 in the 1st half of the year.
According to the Yakup Shinmoon’s(www.yakup.com) analysis ...
Availability of early lunch for ‘Mabthera’ biosimilar in Korea
‘Truxima,’ a biosimilar antibody developed by Celltrion from ‘Mabthera Inj(foreign name: Rituxan),’ got the green light for its early domestic launch as winning a series of patent suits.
Mabthera is a treatment sold ...
SRLRC rules unfair dismissal of employees to Sanofi
Labor-management conflicts continue in multinational pharmaceutical companies. This time, it is a French pharmaceutical company, Sanofi.
The Seoul Regional Labor Relation Commission(SRLRC) ruled a decision of unfair ...
KPDA accuses ‘AhnYeon Care’ having special relation with hospitals
As the pharmaceutical distribution association decided to accuse distribution companies that have special relations with hospitals, its future moves have attracted interests.
The Korea Pharmaceutical Distribution Ass...
Celltrion’s Remsima wins U.S. original drug substance patent conflict
On a summary judgement filed by Celltrion over the Remicade’s substance patent(U.S. Patent No. 6,284,471, hereinafter referring to ‘471 substance patent’), the United States District Court for the District of Massachu...
Reverse strategy to export introduced drug through sales license
The key is just out-of-the-box thinking. While the Pharmerging(pharmacy + emerging) market is considered as a breakthrough to enter the global market, Boryung Pharm’s differentiated export strategy brought an implicat...
Medical field wants to take benefits without efforts while pharma industry is being silent
The medical industry has raised a voice to oppose to tightening the standard related to international academic symposiums held in Korea. Large associations have showed strong disapprovals to the matter, and rather cla...
